| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/28/2005 | WO2005048948A3 Urea derivatives as kinase modulators |
| 07/28/2005 | WO2005048715A3 Organophosphoric compounds and use thereof |
| 07/28/2005 | WO2005047287A3 Bicyclic pyrazolone cytokine inhibitors |
| 07/28/2005 | WO2005046586A3 M3 muscarinic acetylcholine receptor antagonists |
| 07/28/2005 | WO2005046566A3 Stable gabapentin containing composition |
| 07/28/2005 | WO2005044252B1 Pump systems including injectable gabapentin compositions |
| 07/28/2005 | WO2005044198A3 Process and formulation containing epothilones and analogs thereof |
| 07/28/2005 | WO2005042517A3 Bipiperidinyl derivatives useful as inhibitors of chemokine receptors |
| 07/28/2005 | WO2005041944A3 Methods and compositions for promoting axon regeneration and cell replacement therapy |
| 07/28/2005 | WO2005039502A3 Macromer-melt formulations |
| 07/28/2005 | WO2005034866A3 Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors |
| 07/28/2005 | WO2005034838A3 Protease inhibitors |
| 07/28/2005 | WO2005033102A3 Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 07/28/2005 | WO2005033073A3 Spirocyclic heterocyclic derivatives and methods of their use |
| 07/28/2005 | WO2005032528A3 Use of antifungal agents for treating of otitis externa |
| 07/28/2005 | WO2005032234A3 Agent for reducing ill effects of acute alcohol intoxication |
| 07/28/2005 | WO2005031341A3 Methods for predicting development of insulin resistance |
| 07/28/2005 | WO2005030239A3 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
| 07/28/2005 | WO2005027936A3 Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans |
| 07/28/2005 | WO2005027710A3 Methods for identifying subjects at risk of melanoma and treatments thereof |
| 07/28/2005 | WO2005026106B1 Process of hydrocyanation of unsaturated carboxylic acid derivatives |
| 07/28/2005 | WO2005025554A3 Dipeptidyl peptidase iv inhibitor |
| 07/28/2005 | WO2005025512A3 Cobalamin conjugates for anti-tumor therapy |
| 07/28/2005 | WO2005025496B1 Aliphatic pyrazinoylguanidine sodium channel blockers |
| 07/28/2005 | WO2005023216A3 Melt-formulated, multi-particulate oral dosage form |
| 07/28/2005 | WO2005020983A3 Combination therapy for glycaemic control |
| 07/28/2005 | WO2005020932A3 Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| 07/28/2005 | WO2005020881A3 Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases |
| 07/28/2005 | WO2005019224A3 Novel antiinfective compounds |
| 07/28/2005 | WO2005018620A3 Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction |
| 07/28/2005 | WO2005017102A3 Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| 07/28/2005 | WO2005016875A3 Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors |
| 07/28/2005 | WO2005012901A3 Method for measuring aromatase activity |
| 07/28/2005 | WO2005011647A3 Pharmaceutical composition |
| 07/28/2005 | WO2005007110A9 Compositions and methods for hydrophobic drug delivery |
| 07/28/2005 | WO2004112723A3 Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
| 07/28/2005 | WO2004110388A3 Sigma ligands for neuronal regeneration and functional recovery |
| 07/28/2005 | WO2004100893A3 Methods for treatment of inflammatory diseases using ct-3 or analogs thereof |
| 07/28/2005 | WO2004100885A3 Compositions and methods for treating cancer |
| 07/28/2005 | WO2004098498A3 Indole acetic acid derivatives and their use as pharmaceutical agents |
| 07/28/2005 | WO2004093828A3 Reverse-turn mimetics and method relating thereto |
| 07/28/2005 | WO2004075852A3 Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions |
| 07/28/2005 | WO2004064767A3 Nitric oxide inducing agents |
| 07/28/2005 | WO2004060306A3 Anti-inflammatory medicaments |
| 07/28/2005 | WO2004033620A3 Methods and compositions for therapeutic use of rna interference |
| 07/28/2005 | WO2004002296A3 Therapeutic methods for reducing fat deposition and treating associated conditions |
| 07/28/2005 | WO2002096905A8 Thiazole compounds useful as inhibitors of protein kinases |
| 07/28/2005 | WO2002055010A3 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 07/28/2005 | US20050166274 Compositions and methods for the diagnosis and treatment of tumor |
| 07/28/2005 | US20050165256 Aminating compounds such as 3,5-dichloroaniline in the presence of ammonia and a catalyst selected from the group consisting of copper salts, cupric and cuprous oxides and mixtures, heating and pressurization |
| 07/28/2005 | US20050165244 precipitating the citalopram base in crystalline form, and transforming the base into a pharmaceutically acceptable citalopram salt; useful for removing intermediates which are structurally closely related to citalopram |
| 07/28/2005 | US20050165243 Process for the production of an immunosuppressant |
| 07/28/2005 | US20050165242 hydrolysis of atorvastatin lactone with sodium hydroxide to form atorvastatin sodium salt solution; addition to an aqueous calcium chloride or calcium acetate solution; andisolation by filtration and drying; scalable, cost-effective and robust process |
| 07/28/2005 | US20050165240 Chemical intermediates for production of sibutramine |
| 07/28/2005 | US20050165232 Phenyl substituted imidaopyridines and phenyl substituted benzimidazoles |
| 07/28/2005 | US20050165227 Antiproliferative agents; gene overexpression |
| 07/28/2005 | US20050165118 Hypotensive agents; antiinflammatory agents; gastrointestinal disorders; autoimmune disease; 4-phenyl pinene derivatives |
| 07/28/2005 | US20050165117 Hyperforin derivatives, the use thereof and formulations containing them |
| 07/28/2005 | US20050165116 ketones carrying electron withdrawing substituents alpha to the carbonyl functionality; phospholipase A2 inhibitor; potent in reducing eicosanoid production |
| 07/28/2005 | US20050165115 serotonin transporter gene-linked polymorphic region (5HTTLPR) is genotyped; Based on the identified genotype, a particular antidepressant treatment regimen suitable for the patient is determined; kits |
| 07/28/2005 | US20050165113 (3S)-N-butyl-3-((2S)-2-(((4-fluorophenyl)sulfonyl)amino)-3-methylbutanoylamino)-5-methyl-2-oxohexanamide; calpain inhibition; Alzheimer's, osteoporosis, brain and eye disorders, ischemia |
| 07/28/2005 | US20050165112 metalloproteinase inhibitory activity; N-hydroxy-5-ethoxymethyloxy -2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide or a pharmaceutical acceptable salt |
| 07/28/2005 | US20050165111 scleroderma, Buerger's disease, Raynaud's disease, Raynaud's phenomenon; kits |
| 07/28/2005 | US20050165110 Use of treprostinil to improve kidney functions |
| 07/28/2005 | US20050165109 Pharmaceutical composition with combined active agents and methods for using the same |
| 07/28/2005 | US20050165108 reacting D-phenylalanine methylester HCl with trans-4-isopropylcyclohexane carboxylic acid in presence of propane phosphonic acid anhydride or LiOH Al2O3 in a halogenated hydrocarbon solvent such as dichloromethane or dichloroethane; type 2 diabetes mellitus |
| 07/28/2005 | US20050165106 Preferentially inhibit the inducible isoform of nitric oxide synthase |
| 07/28/2005 | US20050165105 Method of using punicic acid to enhance immune response and prevent metabolic disorders |
| 07/28/2005 | US20050165104 Extracted from metalpleural gland from ants; for treating onychomycosis; microbial wipes |
| 07/28/2005 | US20050165103 for enhancing the endogenous production of interleukin-10 (IL-10) and suppressing the production of interleukin-2 in mammalian cells or tissues; inhibiting the proliferation of stimulated peripheral mononuclear cells |
| 07/28/2005 | US20050165102 Improved bioavailability by complexing a drug such as metformin with an ionic moiety such as a fatty acid; e.g. metformin laurate; wrong claims attached to this publication |
| 07/28/2005 | US20050165100 Conjugated fatty acid esters |
| 07/28/2005 | US20050165098 Local anesthetic methods and kits |
| 07/28/2005 | US20050165097 Comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist, for reversing local anesthesia |
| 07/28/2005 | US20050165096 injecting one or more anesthetic and medical drugs into the treatment area under a guidance of the ultrasound imaging tool; massage |
| 07/28/2005 | US20050165095 preventing, treating or ameliorating retinoid poisoning, overdose by a retinoid; e.g. E-4-[3-(8,8-Dimethyl-5-p-tolyl-7,8-dihydro-naphthalen-2-yl)-3-hydroxyimino-propenyl]-benzoic acid (Compound 7a) and Z-4-[3-(8,8-dimethyl-5-p-tolyl-7,8-dihydro-naphthalen-2-yl)-3-hydroxyimino-propenyl]-benzoic Acid |
| 07/28/2005 | US20050165093 Supermolecular carboplatinum derivatives, their preparation and pharmaceutical composition containing tem as active ingredient and applications of the compositions |
| 07/28/2005 | US20050165092 Crystalline base of citalopram |
| 07/28/2005 | US20050165091 includes a buffering agent to stabilize and maintain the pH below 9 in an aqueous dispersion; slow the degradation; shelf-life |
| 07/28/2005 | US20050165090 Polyphenols as an intravesical agent for the prevention of transitional cell tumor implantation |
| 07/28/2005 | US20050165089 Compounds, compositions and methods |
| 07/28/2005 | US20050165088 Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
| 07/28/2005 | US20050165087 Nf-kb inhibitors |
| 07/28/2005 | US20050165086 Aminothiophene inhibitors of NF- kappa B inhibitors for treatment of diseases such as cancer or aids |
| 07/28/2005 | US20050165085 Polymorphic forms of tegaserod base and salts thereof |
| 07/28/2005 | US20050165084 Nitrate derivatives of atorvastatin with improved pharmacological activity and enhanced tolerability; treating coronary syndromes, neurodegenerative disorders, and for reducing cholesterol levels; antiinflammatory, antithrombotic and antiplatelet activity; atorvastatin 4-(nitrooxy)butyl ester |
| 07/28/2005 | US20050165082 Methods of treating vasomotor symptoms |
| 07/28/2005 | US20050165081 for the reduction of the rate of a new contralateral primary tumour |
| 07/28/2005 | US20050165080 Administering a selective imidazoline receptor agonist: moxonidine, rilmenidine, 1,4-diisopropyl-2-(4,5-dihydro-1H-imidazol-2-yl)-piperazine, 1-(4,5-dihydro-1H-imidazol-2-yl)-isoquinoline; treating osteoporosis and hypertension simultaneously; perimenopausal or postmenopausal female |
| 07/28/2005 | US20050165079 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists |
| 07/28/2005 | US20050165077 Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage |
| 07/28/2005 | US20050165074 inhibitors of protein tyrosine kinases, for preventing of cancer, cardiovascular disease, inflammation or multiple sclerosis |
| 07/28/2005 | US20050165072 used as analgesics, antiepileptics agents, antidepressants, antiarrhythmia agents and for treatment of irritable bowel syndrome, Cnohn's disease, multiple sclerosis and bipolar disorders |
| 07/28/2005 | US20050165071 administering two or more timed doses of epothilone b; treating a drug resistant tumor |
| 07/28/2005 | US20050165069 Statine derivatives for the treatment of Alzheimer's disease |
| 07/28/2005 | US20050165068 Compounds, in particularly of urea derivatives or esters of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases |
| 07/28/2005 | US20050165065 N-type calcium channel blockers |
| 07/28/2005 | US20050165064 Novel thiol derivative, process for producing the same and use thereof |
| 07/28/2005 | US20050165058 Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla |
| 07/28/2005 | US20050165056 salt formation; polymorph forms or amorphous forms; antihistamines, antiallergens, bronchodilator agent |